Matches in Ubergraph for { <http://purl.obolibrary.org/obo/NCIT_C132014> ?p ?o ?g. }
Showing items 1 to 29 of
29
with 100 items per page.
- NCIT_C132014 IAO_0000115 "A sustained-release (SR) poloxamer hydrogel formulation containing the glucocorticoid dexamethasone (DXM), with potential otoprotective and anti-apoptotic activities. Prior to the administration of an ototoxic drug and upon intratympanic (IT) injection of the DXM sustained-exposure formulation OTO-104, DXM is slowly released from the hydrogel over time; DMX then binds to glucocorticoid nuclear receptors, and activates cell survival pathways. This prevents ototoxic drug-induced generation of reactive oxygen species (ROS) by activating anti-oxidant enzymes, blocking the activation of inflammatory cytokines and inducing stress signaling pathways, which ultimately prevents apoptosis of auditory hair cells in the inner ear compartment. This prevents or reduces drug-induced ototoxicity caused by certain therapeutic agents, such as platinum-based anticancer agents. This may reduce or prevent hearing loss, tinnitus, and vertigo. The SR formulation provides increased concentrations of DXM in the inner ear and maintains the elevated levels for a longer time without the need of the multiple IT injections needed when using non-SR DXM formulations. This agent also reduces the symptoms of certain ear-related disorders." @default.
- NCIT_C132014 NCIT_A7 NCIT_C17071 @default.
- NCIT_C132014 NCIT_NHC0 "C132014" @default.
- NCIT_C132014 NCIT_P106 "Bacterium" @default.
- NCIT_C132014 NCIT_P106 "Pharmacologic Substance" @default.
- NCIT_C132014 NCIT_P107 "Sustained-Exposure Dexamethasone Formulation OTO-104" @default.
- NCIT_C132014 NCIT_P108 "Sustained-Exposure Dexamethasone Formulation OTO-104" @default.
- NCIT_C132014 NCIT_P208 "CL520548" @default.
- NCIT_C132014 NCIT_P322 "CTRP" @default.
- NCIT_C132014 NCIT_P329 "786798" @default.
- NCIT_C132014 NCIT_P330 "786798" @default.
- NCIT_C132014 NCIT_P399 "786798" @default.
- NCIT_C132014 normalizedInformationContent "100" @default.
- NCIT_C132014 referenceCount "1" @default.
- NCIT_C132014 hasExactSynonym "Dexamethasone Sustained-exposure Formulation OTO-104" @default.
- NCIT_C132014 hasExactSynonym "OTO-104" @default.
- NCIT_C132014 hasExactSynonym "SR DXM Formulation OTO-104" @default.
- NCIT_C132014 hasExactSynonym "Sustained Release Dexamethasone Formulation OTO-104" @default.
- NCIT_C132014 hasExactSynonym "Sustained-Exposure Dexamethasone Formulation OTO-104" @default.
- NCIT_C132014 inSubset NCIT_C116977 @default.
- NCIT_C132014 inSubset NCIT_C116978 @default.
- NCIT_C132014 inSubset NCIT_C176424 @default.
- NCIT_C132014 type Class @default.
- NCIT_C132014 isDefinedBy ncit.owl @default.
- NCIT_C132014 label "Sustained-Exposure Dexamethasone Formulation OTO-104" @default.
- NCIT_C132014 subClassOf NCIT_C132014 @default.
- NCIT_C132014 subClassOf NCIT_C1908 @default.
- NCIT_C132014 subClassOf NCIT_C1909 @default.
- NCIT_C132014 subClassOf NCIT_C26170 @default.